DrugPatentWatch Database Preview

EVOMELA Drug Profile

« Back to Dashboard

When do Evomela patents expire, and when can generic versions of Evomela launch?

Evomela is a drug marketed by Spectrum Pharms and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has thirty-seven patent family members in fourteen countries.

The generic ingredient in EVOMELA is melphalan hydrochloride. There are twelve drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the melphalan hydrochloride profile page.

Summary for EVOMELA

International Patents:	37
US Patents:	3
Applicants:	1
NDAs:	1
Suppliers / Packagers:	1
Clinical Trials:	6
Formulation / Manufacturing:	see details
Drug Prices:	see details
DailyMed Link:	EVOMELA at DailyMed

Pharmacology for EVOMELA

Drug Class	Alkylating Drug
Mechanism of Action	Alkylating Activity

US Patents and Regulatory Information for EVOMELA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Spectrum Pharms	EVOMELA	melphalan hydrochloride	POWDER;IV (INFUSION)	207155-001	Mar 10, 2016		RX	Yes	Yes			Y
Spectrum Pharms	EVOMELA	melphalan hydrochloride	POWDER;IV (INFUSION)	207155-001	Mar 10, 2016		RX	Yes	Yes
Spectrum Pharms	EVOMELA	melphalan hydrochloride	POWDER;IV (INFUSION)	207155-001	Mar 10, 2016		RX	Yes	Yes			Y
Spectrum Pharms	EVOMELA	melphalan hydrochloride	POWDER;IV (INFUSION)	207155-001	Mar 10, 2016		RX	Yes	Yes			Y

Paragraph IV (Patent) Challenges for EVOMELA

Drugname	Dosage	Strength	RLD	Submissiondate
	Injection	50 mg/vial		2017-09-08

Non-Orange Book US Patents for EVOMELA

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
7,635,773	Sulfoalkyl ether cyclodextrin compositions
9,750,822	Sulfoalkyl ether cyclodextrin compositions

International Patents for EVOMELA

Country	Document Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2009134347
Japan	6039721
Hong Kong	1219883
European Patent Office	2748205